| Income statement (USD) | Q3 2026 ended Mar 31, 2026 | Q2 2026 ended Dec 31, 2025 | Q1 2026 ended Sep 30, 2025 | Q4 2025 ended Jun 30, 2025 | Q3 2025 ended Mar 31, 2025 | Q2 2025 ended Dec 31, 2024 | Q1 2025 ended Sep 30, 2024 | Q4 2024 ended Jun 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Research and development | 1.29M | 1.12M | 993.1K | 1.18M | 1.28M | 1.16M | 1.93M | 1.18M |
| Operating expenses | 2.03M | 2.23M | 1.80M | 2.12M | 2.25M | 2.06M | 3.17M | 2.39M |
| Operating income | -2.03M | -2.23M | -1.80M | -2.12M | -2.25M | -2.06M | -3.17M | -2.39M |
| EBITDA | -1.90M | -2.10M | -1.67M | -1.96M | -2.06M | -1.87M | -2.97M | -2.20M |
| Interest expense | 0 | 0 | 149 | 0 | ||||
| Net income | -1.99M | -2.22M | -1.79M | -2.10M | -2.22M | -2.03M | -3.13M | -2.36M |
| EPS | -0.09 | -0.11 | -0.10 | -0.13 | -0.14 | -0.14 | -0.23 | -0.19 |
| EPS (diluted) | -0.09 | -0.11 | -0.10 | -0.13 | -0.14 | -0.14 | -0.23 | -0.19 |
| Diluted shares | 21.61M | 19.85M | 17.08M | 354.7K | 16.03M | 14.57M | 13.72M | 123.1K |
From Nanoviricides, Inc.'s 10-K and 10-Q filings with the SEC. Fourth quarters, and quarters where the company only reported year-to-date totals, are worked out by subtracting the earlier quarters. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read income statement or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.